SAT-458-YI Beneficial impact of consequent non-selective beta-blocker intake on patient outcomes in all stages of chronic liver diseaseJosune Cabello Calleja, Jonel Trebicka, Sabine Klein et al.|Journal of Hepatology|2026Cited by 0
SAT-415 Prognostic utility of circulating macrophage activation markers in primary sclerosing cholangitis: gadget or magic?Dávid Tornai, Maria Papp, Peter van de Ven et al.|Journal of Hepatology|2026Cited by 0
OS-050-YI A genome-wide association study identifies SUSD1 as a risk locus for renal impairment in decompensated cirrhosisLukas Otero Sanchez, P. Martin Padilla, Joan Clãria et al.|Journal of Hepatology|2026Cited by 0
SAT-414-YI Secretory immunoglobulin A (sIgA): a new prognostic marker for primary sclerosing cholangitis (PSC)Dávid Tornai, Maria Papp, Anita Szabó et al.|Journal of Hepatology|2026Cited by 0